Encorafenib

Major

Encorafenib Hydroxyzine Increased risk of QT interval prolongation Details Encorafenib Ibrexafungerp Brexafemme Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Ibrutinib Imbruvica Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Ibutilide Corvert Increased risk of QT interval prolongation Details Encorafenib Idelalisib Zydelig Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Iloperidone Fanapt Increased risk of QT interval prolongation Details Encorafenib Imatinib Gleevec Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Imipramine Increased risk of QT interval prolongation Details Encorafenib Imlunestrant Inluriyo Reduced imlunestrant exposure and reduced efficacy of imlunestrant Details Encorafenib Indinavir Increased encorafenib exposure an increased risk of encorafenib-related adverse events, reduced indinavir exposure and reduced eff... Details Encorafenib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Encorafenib Inotuzumab Ozogamicin Besponsa Increased risk of QT interval prolongation Details Encorafenib Isavuconazole Increased encorafenib exposure and an increased risk of encorafenib-related adverse events; reduced CYP3A4 substrate exposure and... Details Encorafenib Isavuconazonium Cresemba Increased encorafenib exposure and an increased risk of encorafenib-related adverse events; reduced CYP3A4 substrate exposure and... Details Encorafenib Isoflurane Fluriso An increased risk of QT interval prolongation and torsade de pointes Details Encorafenib Itraconazole Sporanox Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Ivabradine Corlanor Reduced CYP3A4 substrate exposure, reduced efficacy of CYP3A4 substrate and an increased risk of QT interval prolongation Details Encorafenib Ivacaftor Kalydeco Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Ivosidenib Tibsovo Reduced encorafenib exposure, reduced efficacy of encorafenib and an increased risk of QT interval prolongation Details Encorafenib Lapatinib Tykerb Increased risk of QT interval prolongation Details Encorafenib Lazertinib Lazcluze Reduced lazertinib exposure and reduced efficacy of lazertinib Details Encorafenib Lefamulin Xenleta Increased risk of QT interval prolongation Details Encorafenib Lemborexant Dayvigo Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Leniolisib Joenja Reduced leniolisib exposure and reduced efficacy of leniolisib Details Encorafenib Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Encorafenib Letermovir Prevymis Increased encorafenib/letermovir exposure, an increased risk of encorafenib-related adverse events and an increased risk of leterm... Details Encorafenib Leuprolide Eligard Increased risk of QT interval prolongation Details Encorafenib Levofloxacin Levaquin Increased risk of QT interval prolongation Details Encorafenib Levomethadyl Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Levonorgestrel After banger Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Lofexidine Increased risk of QT interval prolongation Details Encorafenib Lomitapide Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Lonafarnib Zokinvy An increased risk of QT interval prolongation and torsade de pointes, increased encorafenib exposure and an increased risk of enco... Details Encorafenib Loperamide Diamode An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Encorafenib Lopinavir Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Lovastatin Altocor® Altered (increased or reduced) lovastatin exposure, increased risk of lovastatin-related toxicities and reduced efficacy of lovast... Details Encorafenib Lumacaftor Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Lumateperone Caplyta Reduced lumateperone exposure Details Encorafenib Lumefantrine Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy and an inc... Details Encorafenib Lurasidone Latuda Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details